Delta variant, the Johnson & Johnson vaccine protects. This is said by the American manufacturer itself, explaining that it develops “a neutralizing antibody activity against the Delta variant” of the Sars-CoV-2 coronavirus, “at an even higher level than that recently observed for the Beta variant in South Africa, where it has been shown to be highly effective against severe / critical forms of the disease “. The information was released by J&J, announcing the data of a pre-publication presented today by the US company to the pre-print platform ‘bioRxiv’, relating to “a new analysis of blood samples obtained from a subset of participants (8) Phase 3 Ensemble Studio “. Duration of protection “The humoral and cellular immune responses generated by Janssen’s single-dose anti-Covid vaccine lasted for at least 8 months” according to “the last observation reported to date”. “The data showed that T cell responses – including CD8 + cells that recognize and destroy infected cells – are persistent over the 8 months tested.” “The current data so far reaches 8 months of observation and shows that Johnson & Johnson’s single dose vaccine against Covid-19 generates a strong neutralizing antibody response that does not decrease over time; indeed, an increase is observed – says Mathai Mammen. Global Head, Janssen Research & Development, J&J – In addition, we see a persistent and particularly robust and long-lasting cellular immune response. “” With each new dataset – he concludes – we strengthen the evidence base showing that our single dose vaccine against Covid-19 plays a fundamental role in being able to put an end to the pandemic, which continues to evolve and launch new challenges to global health “.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.